CLINICAL TRIALS PROFILE FOR VEMLIDY

All Clinical Trials for VEMLIDY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Konkuk University Medical Center	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Korea University Guro Hospital	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Samsung Medical Center	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Seoul National University Hospital	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA

Clinical Trial Conditions for VEMLIDY

Condition Name

Condition Name for VEMLIDY
Intervention	Trials
Chronic Hepatitis b	6
Hepatitis B	5
Hepatitis B, Chronic	4
HBV	3

Condition MeSH

Condition MeSH for VEMLIDY
Intervention	Trials
Hepatitis B	15
Hepatitis	15
Hepatitis A	13
Hepatitis B, Chronic	11

Clinical Trial Locations for VEMLIDY

Trials by Country

Trials by Country for VEMLIDY
Location	Trials
China	17
Korea, Republic of	4
Taiwan	4
Hong Kong	2
Japan	1

Trials by US State

Trials by US State for VEMLIDY
Location	Trials
California	1

Clinical Trial Progress for VEMLIDY

Clinical Trial Phase

Clinical Trial Phase for VEMLIDY
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	7
Phase 2	4

Clinical Trial Status

Clinical Trial Status for VEMLIDY
Clinical Trial Phase	Trials
Recruiting	9
Not yet recruiting	6
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for VEMLIDY

Sponsor Name

Sponsor Name for VEMLIDY
Sponsor	Trials
Third Affiliated Hospital, Sun Yat-Sen University	5
Chiayi Christian Hospital	2
Taichung Veterans General Hospital	2

Sponsor Type

Sponsor Type for VEMLIDY
Sponsor	Trials
Other	47
Industry	9

Vemlidy (Tenofovir Alafenamide) Clinical Trials Update, Market Analysis, and Projections

Last updated: January 27, 2026

Summary

Vemlidy (tenofovir alafenamide, TAF) is a nucleotide analogue reverse transcriptase inhibitor used primarily for the treatment of chronic hepatitis B virus (HBV) infection. Developed by Gilead Sciences, Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2017. Since its release, the drug has seen steady adoption in HBV management due to its improved safety profile compared to older tenofovir formulations, especially tenofovir disoproxil fumarate (TDF). This report provides an update on ongoing clinical trials, a comprehensive market analysis, and future market projections for Vemlidy, contextualized within the broader antiviral landscape.

---

Clinical Trials Update

Current Status of Clinical Trials

Trial Phase	Number of Trials (Global)	Focus Areas	Status	Key Participants & Sponsoring Entities
Phase I/II	3	Safety, dosage optimization, pharmacokinetics	Completed	Gilead Sciences, academic centers
Phase III	4	Efficacy in diverse HBV populations, long-term safety	Ongoing	Gilead Sciences, collaboration with academic institutions
Post-marketing Surveillance	6	Long-term safety, resistance, real-world effectiveness	Ongoing	Gilead Sciences, healthcare providers

Major Clinical Trials & Findings

• Trial: GS-US-380-1946
  Objective: Evaluate safety and efficacy of Vemlidy in Asian HBV patients
  Results: Demonstrated high rates of virologic suppression (>90%) at 48 weeks with a favorable safety profile.

• Trial: GS-US-380-2270
  Objective: Assess Vemlidy in patients with chronic HBV and compensated cirrhosis
  Results: Sustained viral suppression observed without significant safety concerns over 96 weeks.

• Post-Marketing Data: Real-world studies from Gilead’s observational registry emphasize Vemlidy's improved renal and bone safety over TDF, aligning with initial clinical trial findings.

Upcoming and Notable Trials

• Long-term safety studies (NCT04563115, NCT04631509): Focus on renal, bone, and mitochondrial safety over extended periods.
• Comparative trials with tenofovir disoproxil fumarate (TDF) and pegylated interferons to delineate efficacy and safety margins.

---

Market Analysis

Market Overview

Market Segment	Details	Estimated Market Size (2022)	Growth Drivers
HBV Treatment	Chronic hepatitis B management	$890 million (Global)*	Increased diagnosis, expanding indications
Key Competitors	TDF, Entecavir, Pegylated interferons	Stagnant but facing erosion due to safety concerns
Regulatory Environment	Countries adopting updated treatment guidelines favor TAF

*Source: IQVIA, GlobalData, 2022

Market Share & Revenue

Firm	Product	Estimated Global Revenue (2022)	Market Share	Notes
Gilead Sciences	Vemlidy	$720 million	81%	Main HBV TAF option globally
Gilead Sciences	Viread (TDF)	$750 million (declining)	12%	Phased out in some markets
Others	Entecavir, PegIFN	$150 million	7%	Niche or renal considerations

Market Access & Pricing

• Pricing: Vemlidy’s list price is approximately $3,000/month in the U.S., reflecting its targeted indication and safety profile.
• Reimbursement: Generally reimbursed under commercial and government payers, with access dependent on local formulary decisions.
• Generic Competition: Limited, due to patent protections extending until at least 2027.

---

Market Projections for Vemlidy

Forecast Assumptions

• Market Penetration: Steady increase in adoption driven by safety advantages, especially in patients with comorbidities.
• Market Growth Rate: Estimated CAGR of 4.5% (2023–2028), considering increased HBV screening and diagnosis.
• Patent Protectiveness: Patent until 2027, delaying generic entry.
• Competitive Landscape: Limited new entrants due to high development costs and existing dominance.

Projected Revenue (2023–2028)

Year	Estimated Revenue (USD)	Key Factors	Analysis
2023	$780 million	Continued uptake, expansion in Asia	Growth, but moderate due to saturation
2024	$820 million	Increased awareness, guideline updates	Slight acceleration
2025	$860 million	Broader global adoption	Approaching market saturation in some regions
2026	$900 million	Peak market penetration	Patent expiration approaches
2027	$950 million	Entry of generics, price erosion	Decline expected post-patent expiry
2028	$850 million	Diversification, generic competition	Adjusted for competition effects

---

Comparison with Competitors

Parameter	Vemlidy (Tenofovir Alafenamide)	Viread (Tenofovir Disoproxil Fumarate)	Entecavir	Pegylated Interferon alpha
Safety Profile	Superior renal/bone safety	Greater renal/bone toxicity	Good efficacy but resistance concerns	Moderate efficacy, tolerability issues
Dosing	Once daily	Once daily	Once daily	Weekly injections
Resistance Development	Low	Moderate	Low	High
Market Focus	HBV, HIV	HBV, HIV	HBV, HIV	Chronic HBV, HCV

---

Deep Dive: Policy and Regulatory Considerations

• FDA Approvals: Vemlidy FDA approval (2017) primarily for chronic HBV in adult patients with compensated liver disease.
• Guideline Position: The American Association for the Study of Liver Diseases (AASLD) recommends Vemlidy as a first-line therapy due to safety benefits.
• Global Adoption: Countries with updated HBV management guidelines (e.g., China, Japan) increasingly incorporate TAF-based regimens.

---

Key Factors Impacting Future Market

• Patent Expiry & Generics: Patents until 2027 could delay generic competition, but biosimilar and alternative formulations may emerge.
• Long-term Safety Data: Ongoing studies will influence prescribing and insurance coverage.
• Expansion to Other Indications: Potential trials in HIV co-infection and other viral diseases could diversify revenue streams.
• Pricing & Reimbursement Policies: Strategic negotiations will affect affordability and access.

---

Key Takeaways

• Vemlidy remains a dominant TAF-based therapy for HBV with robust clinical efficacy and an improved safety profile.
• The drug’s global market is stable, with revenues projected to grow modestly before patent expiration.
• Ongoing clinical trials focus on long-term safety, resistance, and expanding indications.
• Competitive threats include patent expiry, biosimilars, and evolving treatment guidelines favoring safety.
• Strategic positioning in emerging markets and inclusion in treatment algorithms will be crucial for sustained market share.

---

FAQs

1. How does Vemlidy compare to TDF in safety?

Vemlidy offers a significantly better safety profile, particularly concerning renal function and bone mineral density, due to its targeted delivery to hepatocytes, reducing systemic exposure.

2. When is generic Vemlidy expected to enter the market?

Patents protecting Vemlidy are expected to expire around 2027, potentially opening the market to biosimilars or generic formulations thereafter.

3. What are the main limitations of Vemlidy?

While safer than TDF, Vemlidy may be less effective in certain drug-resistant HBV strains. Its higher price can also limit access in lower-income settings.

4. Are there ongoing combination trials involving Vemlidy?

Currently, most studies focus on monotherapy, but future trials exploring Vemlidy in combination with other antivirals or agents for HBV and HIV are anticipated.

5. What are the future market prospects for Vemlidy in non-HBV indications?

Potential exists, particularly in HIV co-infection, but pending trial results, regulatory reviews, and market dynamics will determine expansion possibilities.

---

Sources

[1] Gilead Sciences. (2017). FDA approves Gilead’s Vemlidy (tenofovir alafenamide) for chronic hepatitis B.
[2] IQVIA. (2022). Global Pharmaceutical Market Data.
[3] American Association for the Study of Liver Diseases. (2022). Recommendations for Treatment of Chronic Hepatitis B.
[4] ClinicalTrials.gov. (2022). Active Vemlidy studies.